ClinicalTrials.gg
RecruitingNCT06842446DVT-SMARTUpdated Nov 10, 2026

Systematic Machine Learning Algorithm for Rapid Thrombosis Detection

An interventional study of POC D-dimer and POC ultrasound in Deep Vein Thrombosis, sponsored by Ostfold Hospital Trust. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Ostfold Hospital Trust · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare the use of a machine learning-based algorithm and point-of-care D-dimer to laboratory D-dimer and compression ultrasound to exclude deep vein thrombosis in the under extremities in patients referred to a medical department suspected of having deep vein thrombosis. The main aim is to answer are if a machine learning algorithm and point of care D-dimer can exclude deep vein thrombosis in more patients than clinical assessment and D-dimer alone.

Read the detailed description

All participants will follow the usual diagnostic algorithm used for patients with suspected DVT referred to Ostfold Hospital (all patients are examined by a physician, D-dimer is analyzed in all patients, ultrasound is performed by a radiologist in patients with positive D-dimer). In addition to usual care, POC D-dimer, POC ultrasound (performed by ED physicians), blood sampling for biobanking, and photographies of the under extremities will be performed. The machine learning model will be tested to see if the prediction is correct. In participants where ultrasound is performed, it will also be assessed whether the machine learning algorithm could have excluded the participant without the use of ultrasound. None of the additional procedures will have any impact on the patient diagnostics or treatment.

02

Conditions studied

  • Deep Vein Thrombosis

Browse trials for

Keywords

  • Machine Learning
  • POC D-dimer
  • POC Ultrasound
03

In context

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.

Browse Venous Thrombosis studies →

Lead sponsor

Ostfold Hospital Trust is the lead sponsor of 50 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients referred to the ED due to suspicion of DVT
  • Age ≥ 18 years
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • Ongoing use of anticoagulation for more than 72 hours
  • Previous participation in the study
  • of less than three months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    All participants

    All participants will be treated the same way.

    Diagnostic Test: POC D-dimer · Diagnostic Test: POC ultrasound · Diagnostic Test: Machine learning model

Interventions

  • Diagnostic testPOC D-dimer

    POC D-dimer will be compared to laboratory D-dimer in hospital setting and used in a machine learning model

  • Diagnostic testPOC ultrasound

    Point of care (POC) ultrasound performed by ED physicians compared to ultrasound performed by radiologist. POC ultrasound 3 point examination performed by ED physician will be compared with POC ultrasound full leg examination performed by ED physician.

  • Diagnostic testMachine learning model

    The DSS will be compared to the usual strategy. It will also be estimated how many participants where DVT could have been excluded without ultrasound.

    Also known as: Decision support system

06

What researchers measure

Primary outcomes

  1. Safety of the new strategy (POC D-dimer, ML-based prediction model, POC CUS by emergency physician)

    Evaluate the safety of a new strategy consisting of POC D-dimer and an ML-based prediction model followed by CUS performed by emergency physicians by comparing the new strategy's safety with our standard care by measuring the proportion of patients in whom DVT is excluded according to the new strategy but was diagnosed with DVT by standard care or in whom DVT is diagnosed within the 90-day follow up.

    Time frame: From enrollment to the end of the primary assessment period (90 days)

Secondary outcomes

  1. Evaluate the efficiency of the new strategy

    The proportion of patients in whom DVT can be ruled out by the ML-based prediction model with POC D-dimer compared to the efficiency of Wells score and laboratory D-dimer

    Time frame: From enrollment to the end of the primary assessment period (90 days)

  2. Validate the safety and efficiency of the ML-based prediction model

    Safety will be determined by the proportion of patients in whom DVT is excluded by the ML-model but diagnosed by standard care. Efficiency will be determined by the proportion of patients in whom DVT can be excluded by the ML-based model

    Time frame: From enrollment to the end of the primary assessment period (90 days)

  3. Evaluate concordance between CUS performed by emergency physicians and radiologists.

    Determine the proportion of false negative and false positive diagnosis of DVT in emergency physician-performed ultrasound compared with ultrasound performed by radiologists.

    Time frame: From time of enrollment until time of ultrasound examination performed by radiologist, assessed up to 48 hours.

  4. Evaluate concordance between POC D-dimers in an ED setting and laboratory D-dimers.

    Compare the two POC D-dimers with the STA-Liatest D-dimer and Siemens INNOVANCE by direct comparison of the true/false positive/negative results.

    Time frame: From enrollment to the completion of D-dimer analysis, assessed up to 24 hours.

  5. Evaluate the hypothetical time to be completed for the novel strategy compared to the standard strategy.

    Estimating the total management time defined as time from ED registration to ED discharge in patients evaluated according to the new strategy compared to standard care.

    Time frame: From time of enrollment until time of discharge from the emergency department either discharged from the hospital or hospitalized, assessed up to 24 hours.

  6. Evaluate the safety of a limited ultrasound protocol (two-point and proximal) compared to full-leg CUS performed by emergency physicians and radiologists

    Estimating the proportion of patients in whom DVT was ruled out by the limited ultrasound protocol but was diagnosed with DVT by the whole-leg ultrasound.

    Time frame: 90 days after enrollment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The plan to share IPD with other researchers are not yet decided because it has not yet been discussed.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Apr 2027, 26 months after the start.

Of 99 non-industry interventional studies with no phase under Venous Thrombosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 26 months is below that.

Counting every sponsor, half of 117 studies reached it within 34 months; a quarter within 13 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jan 2027 → Apr 2027 and completion Jan 2029 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Feb 24, 2025
StartActual
Jan 6, 2025
Primary completionEst.
Apr 5, 2027was Jan 2027
CompletionEst.
Apr 5, 2029was Jan 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 5, 2027→Apr 5, 2027
Nov 10, 2026
Study completion
Jan 5, 2029→Apr 5, 2029
Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Østfold Hospital Trust · Sarpsborg, NorwayContact person changed (no phone or email listed)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Jan 5, 2027→Apr 5, 2027
    Study completion Jan 5, 2029→Apr 5, 2029
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Østfold Hospital Trust · Sarpsborg, NorwayContact person changed (no phone or email listed)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06842446
Lead sponsor
Ostfold Hospital Trust
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Jan 6, 2025
Primary completion
Apr 5, 2027 (estimated)
Completion
Apr 5, 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Waleed Ghanima, Professor
Contact
waleed.ghanima@so-hf.no
69860000 ext. 0047
Hans Joakim Myklebust-Hansen, Medical Doctor
Contact
hans.joakim.hansen@so-hf.no
97501765 ext. 0047

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion